Elmiron® Bladder Pain Lawsuit
Elmiron® Medication Lawsuits and Settlements
Victims have suffered maculopathy or other serious eye damage.
ELMIRON® LAWSUIT INFORMATION
*Elmiron® is the only FDA approved oral medication designed to treat bladder pain associated with interstitial cystitis (IC), a condition that affects millions of Americans each year. A study published in October 2019 by the American Academy of Ophthalmology links Elmiron® to toxic retina eye issues.
If you or a loved one developed vision problems after taking Elmiron®. You could be owed money if you suffered complications as a result.
Signs & Symptoms:
- Blurred vision
- Degenerative maculopathy
- Difficulty adjusting to darkness
- Eye pain
- Halo vision
- Macular retinopathy
- Vision loss
- And more…
If you were prescribed Elmiron® and developed vision problems after taking Elmiron®, you may be entitled to significant financial compensation!
Do not stop taking your medication without first consulting with your physician. Doing so could result in injury or death.
If you or a loved one used Elmiron® and suffered complications as a result, you could be owed money.
CALL NOW FOR A FREE CLAIM REVIEW at (800) 203-5107
Don’t wait, call now! You may be entitled to the financial compensation you deserve.
WHAT IS ELMIRON®:
Elmiron® is a commonly prescribed weak blood thinner (anti-coagulant) that is used to treat bladder pain or discomfort caused by cystitis of the bladder. It contains the active ingredient pentosan polysulfate sodium (PPS). Approved by the U.S. Food and Drug Administration (FDA) in 1996, pentosan polysulfate sodium (Elmiron®) is the only FDA approved oral medication designed to treat bladder pain and discomfort associated with interstitial cystitis (IC), a condition that affects millions of Americans each year. IC is more prevalent in women, and many use Elmiron® long-term to treat the disease. Elmiron® sales amount to at least $150 Million per year.
**In November 2018, the American Academy of Ophthalmology released a study that found a connection between long-term use of Elmiron® and vision problems. Another Elmiron® study released in May 2019 concluded that Elmiron® resulted in “potentially avoidable retinal degeneration phenomenon associated with chronic [Elmiron®] exposure.” Then the American Academy of Ophthalmology published another study in October 2019, which found that Elmiron® (pentosan polysuflate sodium) “appears to be toxic to the retina” and that about one-quarter of Elmiron® users may suffer from a form of macular degeneration or “Maculopathy.” Maculopathy is any disease that impacts the macula, which is the central part of the retina that is responsible for all central vision, most color vision, and fine detail. The type of maculopathy linked to Elmiron® is called pigmentary maculopathy, which according to studies, seems to be unique to Elmiron® users. If caught in its early stages, the damage may stop after taking medication but in late stages, the disease can lead to permanent vision loss. So far researchers have reported on one patient whose eye damage continued for years even after stopping Elmiron®.